| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.81▲ | 5.77▲ | 5.77▲ | 5.75▲ | 5.66▲ |
| MA10 | 5.77▲ | 5.76▲ | 5.75▲ | 5.84▲ | 5.48▲ |
| MA20 | 5.75▲ | 5.74▲ | 5.70▲ | 5.60▲ | 5.07▲ |
| MA50 | 5.73▲ | 5.86▼ | 5.76▲ | 5.44▲ | 4.05▲ |
| MA100 | 5.87▼ | 5.69▲ | 5.25▲ | 4.95▲ | N/A |
| MA200 | 5.66▲ | 4.68▲ | 4.38▲ | 4.18▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.013▲ | 0.019▲ | 0.015▲ | 0.014▲ | 0.021▲ |
| RSI | 58.667▲ | 55.414▲ | 55.977▲ | 56.815▲ | 71.527▲ |
| STOCH | 71.093 | 68.242 | 76.136 | 27.860 | 48.025 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -63.547 | -55.844 |
| CCI | 169.582▲ | 215.030▲ | 189.268▲ | 30.744 | 105.048▲ |
|
Tuesday, September 30, 2025 07:41 AM
Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and strong safety, supporting Phase 2b expansion.
|
|
Monday, September 29, 2025 05:40 PM
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in ...
|
|
Wednesday, September 24, 2025 05:54 AM
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 5.80 | 5.95 | 5.59 | 5.90 | 132,300 |
| 29/09/25 | 5.78 | 5.78 | 5.55 | 5.75 | 15,801 |
| 26/09/25 | 5.84 | 5.84 | 5.60 | 5.74 | 58,500 |
| 25/09/25 | 5.51 | 5.91 | 5.3908 | 5.76 | 90,512 |
| 24/09/25 | 5.76 | 5.97 | 5.16 | 5.59 | 419,400 |
| 23/09/25 | 5.65 | 6.41 | 5.65 | 5.66 | 980,723 |
| 22/09/25 | 6.28 | 7.19 | 5.98 | 6.65 | 330,300 |
| 19/09/25 | 6.20 | 6.20 | 5.822 | 5.96 | 37,614 |
| 18/09/25 | 5.47 | 6.31 | 5.41 | 6.04 | 185,000 |
| 17/09/25 | 5.399 | 5.41 | 5.35 | 5.38 | 7,600 |
|
|
||||
|
|
||||
|
|